Last ¥3,055 JPY
Change Today -95.00 / -3.02%
Volume 1.4M
4519 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 2:00 AM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

chugai pharmaceutical co ltd (4519) Snapshot

Open
¥3,125
Previous Close
¥3,150
Day High
¥3,160
Day Low
¥3,055
52 Week High
08/18/14 - ¥4,015
52 Week Low
01/28/14 - ¥2,107
Market Cap
1.7T
Average Volume 10 Days
1.8M
EPS TTM
¥101.04
Shares Outstanding
559.7M
EX-Date
12/26/14
P/E TM
30.2x
Dividend
¥45.00
Dividend Yield
1.47%
Current Stock Chart for CHUGAI PHARMACEUTICAL CO LTD (4519)

Related News

No related news articles were found.

chugai pharmaceutical co ltd (4519) Related Businessweek News

No Related Businessweek News Found

chugai pharmaceutical co ltd (4519) Details

Chugai Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in Japan and internationally. Its products in oncology include Avastin, Herceptin, Rituxan, Xeloda, Tarceva, Neutrogin, and Perjeta; bone and joint disease products comprise Actemra, Suvenyl, Edirol, Alfarol, and Bonviva; renal disease products consist of Mircera, Oxarol, and Epogin; and other products, such as Tamiflu, Sigmart, CellCept, Pegasys, and Copegus. The company has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, central nervous system, respiratory diseases, and other diseases. Chugai Pharmaceutical Co., Ltd. has a strategic alliance with Roche; and co-development agreement with Taisho Pharmaceutical Co., Ltd., as well as co-marketing agreement with Taisho Toyama Pharmaceutical Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

6,872 Employees
Last Reported Date: 03/27/14
Founded in 1925

chugai pharmaceutical co ltd (4519) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥266.0M
President, Chief Operating Officer and Repres...
Total Annual Compensation: ¥74.0M
Compensation as of Fiscal Year 2013.

chugai pharmaceutical co ltd (4519) Key Developments

Chugai Denies Rumor Of Talks With Roche

Chugai Pharmaceutical Co. Ltd. (TSE:4519) denies a rumor that Roche Holding AG (SWX:ROG) was in talks to buy 40% stake of Chugai Pharmaceutical that it does not already own for $10 billion.

Roche Holding Reportedly In Talks To Chugai Pharmaceutical

Roche Holding AG (SWX:ROG) is in talks to buy the almost additional 40% stake in Chugai Pharmaceutical Co. Ltd. (TSE:4519) for about $10 billion, Bloomberg reported citing people familiar with the matter. A deal could be announced as early as next week, although no final decision has been made. A Chugai Pharmaceutical Co. Ltd.'s statement said the company is “in no way in the process of reviewing any plan to become a wholly owned subsidiary of Roche.” Representatives for Roche Holding AG declined to comment.

Chugai Pharmaceutical Co. Ltd., Q2 2014 Earnings Call, Jul 25, 2014

Chugai Pharmaceutical Co. Ltd., Q2 2014 Earnings Call, Jul 25, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4519:JP ¥3,055.00 JPY -95.00

4519 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4519.
View Industry Companies
 

Industry Analysis

4519

Industry Average

Valuation 4519 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHUGAI PHARMACEUTICAL CO LTD, please visit www.chugai-pharm.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.